Abram Scientific's Rapid Test Aims to Revolutionize Trauma Care

MENLO PARK, CA – February 25, 2026 – Medical device innovator Abram Scientific has secured $11.75 million in a Series A funding round to accelerate the development of a technology that could fundamentally change how emergency medicine is practiced. The financing, led by global pharmaceutical giant Octapharma AG, will propel the company's portable diagnostic platform, CoagCare™, through crucial clinical and regulatory milestones.

The device is designed to deliver a complete analysis of a patient's blood clotting ability in under 10 minutes from a single drop of blood. This represents a monumental leap in speed compared to current standards, promising to give clinicians critical information for life-saving decisions in trauma situations, major surgeries, and for patients with bleeding disorders.

A New Era for Emergency Diagnostics

In the high-stakes world of emergency medicine, particularly in trauma care, time is the most critical and unforgiving variable. Uncontrolled bleeding, or hemorrhage, remains a leading cause of preventable death in trauma patients. The ability to quickly understand why a patient is bleeding—and how to stop it—is paramount. For decades, the gold standard for assessing blood coagulation has been platforms like thromboelastography (TEG®) and thromboelastometry (ROTEM®). While effective, these systems are typically large, lab-based instruments that require 30 to 60 minutes to provide a full picture of the blood's clotting process, including the breakdown of clots (fibrinolysis).

Abram Scientific aims to shatter this time barrier. Its CoagCare™ system is a handheld, point-of-care meter that uses a single-use test card. The platform employs proprietary technology to measure blood viscoelasticity and density, providing a complete characterization of the coagulation cascade in less than 10 minutes. This dramatic reduction in turnaround time could empower first responders and emergency physicians to administer targeted therapies—such as blood products or clotting factors—with unprecedented speed and precision.

"Uncontrolled hemorrhage remains one of the leading—and most preventable—causes of early trauma death," said Dr. Vik Bebarta, Endowed Chair in Emergency Medicine at the University of Colorado Anschutz and Founding Director of The Center for COMBAT Research, a key collaborator. "We are excited to partner with Abram Scientific to develop CoagCare to give surgeons and emergency physicians the critical information they need sooner to guide life-saving therapy decisions."

Furthermore, the device's design addresses another major limitation of current systems: portability. Engineered to be vibration-insensitive, CoagCare™ is intended for use far beyond the stable confines of a hospital laboratory. This opens the door for advanced diagnostic capabilities in pre-hospital settings like ambulances and MEDEVAC helicopters, where rapid assessment can be the difference between life and death before a patient even reaches the hospital.

Octapharma's Strategic Pivot into Diagnostics

The leadership of the funding round by Octapharma AG is perhaps as significant as the technology itself. Octapharma is a powerhouse in the world of human protein therapies, manufacturing life-saving treatments for hematology and critical care from human plasma. However, its business has historically focused squarely on therapeutics, not diagnostics. This $11.75 million investment marks the company's first major foray into the diagnostics sector, signaling a strategic evolution.

The move reflects a broader industry trend toward creating integrated healthcare solutions that span the entire continuum of patient care. By investing in a rapid diagnostic tool that complements its existing portfolio of critical care therapies, Octapharma is positioning itself to not only provide the treatment but also to guide its optimal use. This synergy could lead to more personalized medicine, reducing the risks of over- or under-treatment and improving patient outcomes.

"Abram's CoagCare can empower clinicians to deliver goal-oriented therapy with greater accuracy, ensuring the right intervention, at the right time, in the right amount," stated Flemming Nielsen, President of Octapharma USA, Inc. "This represents an important step forward in patient care and can help shape clinical guidelines nationally and globally."

For Octapharma, this investment is a calculated expansion that diversifies its business model and deepens its footprint in the acute care setting. It allows the company to move beyond simply supplying a product to actively participating in the clinical decision-making process, a strategy that could provide a significant competitive advantage and pave the way for future ventures that bridge the gap between diagnostics and therapeutics.

The Path to Market: Navigating Regulation and Innovation

With fresh capital in hand, Abram Scientific's immediate focus is on advancing the CoagCare™ system toward commercialization. A critical part of this journey is securing 510(k) clearance from the U.S. Food & Drug Administration (FDA), a process the funding is explicitly intended to support. This regulatory pathway requires the company to demonstrate that its device is substantially equivalent in safety and effectiveness to a legally marketed predicate device. For a technology as novel as CoagCare™, this can be a complex undertaking. The FDA will likely scrutinize its performance, particularly given its intended use in high-risk, non-laboratory environments. Proving the device's accuracy and reliability across varied conditions, from a vibrating ambulance to a chaotic emergency room, will be essential.

"Our mission is to enable CoagCare to help adjudicate life-saving therapies and transfusions, so that the right therapy is provided to the patient at the right time and at the right dosage," said Abhishek Ramkumar, the CEO, Founder, and inventor of the CoagCare platform. He emphasized that the collaboration with Octapharma and the University of Colorado provides both the capital and strategic expertise needed to "revolutionize the current clinical paradigm."

Protecting this paradigm-shifting technology is a robust intellectual property portfolio. The company holds 17 granted U.S. and international patents, with more applications pending. This strong IP position creates a formidable barrier to entry for competitors and secures the company's innovative edge as it moves through the final stages of development and prepares to enter the market. As Abram Scientific pushes forward, the medical community watches with anticipation for a tool that promises to bring lab-grade precision to the front lines of emergency care, saving time and, ultimately, saving lives.